Company news

Recce Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

License and Commercialisation Agreement in AUS/NZ for R327G

October 21, 2026

License and Commercialisation Agreement in AUS/NZ for R327G

October 21, 2026

Independent Review of Indonesian Phase 3 R327G Trial Data

October 19, 2026

Independent Review of Indonesian Phase 3 R327G Trial Data

October 19, 2026

Amendments to Debt Facility with Avenue Capital Group

October 16, 2026

Amendments to Debt Facility with Avenue Capital Group

October 16, 2026

Appendix 4E and FY26 Annual Report

August 31, 2026

HREC Approves Comparator Study for Pivotal Phase 3 DFI

August 18, 2026

Vietnamese Patent Granted for RECCE Anti-Infectives

July 13, 2026

AUD $3.7M Income Tax Refund Received

June 30, 2026

Placement & SPP to raise $8 million

June 25, 2026

HREC Approval Accelerates Global Phase 3 DFI Strategy

June 21, 2026

Addendum to Recce Signs Middle East Licensing Term Sheet

May 27, 2026

Recce Signs Middle East Licensing Term Sheet

May 26, 2026

Brazil Patent Granted for RECCE Anti-Infectives

March 24, 2026

RCE Investor Webinar Presentation Deck

March 19, 2026

Appendix 4D and Interim Financial Report

February 27, 2026

Recce Enters Second U.S. Department of Defense R&D Agreement

February 1, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 30, 2026

AUD $5.3m R&D Rebate Received

January 13, 2026

RCE Awarded Advanced Overseas Finding up to A$85m

December 15, 2025

Hong Kong Patent Granted for RECCE Anti-Infectives

November 26, 2025

Positive Efficacy Data for Inhaled R327 in HAP/VAP Model

November 25, 2025

Patient Dosing Underway in Ph 3 Indonesia DFI Trial

September 25, 2025

Preliminary Final Report

August 29, 2025

R327G Highly Effective in Burn Wounds Model

August 12, 2025

Recce Signs Debt Facility with Avenue Capital Group

June 17, 2025

Successful Placement of Entitlement Offer Shortfall

June 3, 2025

China Patent Accepted for RECCE Anti-Infectives

May 26, 2025

Recce Enters into USA Department of Defense R&D Agreement

April 27, 2025

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

April 23, 2025

Entitlement Offer - Offer Booklet and Access Letter

April 22, 2025

Phase II Clinical Trial Receives Additional Approval for DFI

April 22, 2025

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

April 10, 2025

Placement and Entitlement Offer to Fund Phase III Trials

April 10, 2025

Key Opinion Leader Presentation

March 2, 2025

Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives

February 27, 2025

Japan Patent Allowance for RECCE Anti-Infectives

February 25, 2025

Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway

February 19, 2025

Positive Phase II Data from Clinical Trial of R327 Gel

February 16, 2025

Trading Halt

February 13, 2025

Pause in Trading

February 13, 2025

Correction to Appendix 4C and Quarterly Activities Report

February 6, 2025

Patient Dosing Complete in Phase II ABSSSI Trial of R327G

January 20, 2025

Regulatory Approval for Registrational Phase 3 R327G Trial

December 8, 2024

Australia Patent Granted for RECCE Anti-Infectives

November 25, 2024

AUD $6.75m R&D Rebate Approved

November 13, 2024

Ethics Approval for Registrational Ph3 R327G Clinical Trial

November 10, 2024

Older news releases →

Decks

The 5 newest of 26 decks. Every deck is listed under its year.